Status:
COMPLETED
Multiple Dose Study of MPC-6827 in Subjects With Refractory Brain Metastases
Lead Sponsor:
Myrexis Inc.
Conditions:
Brain Neoplasms
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
Phase 1, Multiple dose Study of MPC-6827 in Subjects with Refractory Brain Metastases.
Eligibility Criteria
Inclusion
- Refractory Brain Metastases
- At least 1 measurable intracranial lesion as defined by RECIST
- ECOG less than or equal to 1
- Adequate hematology/organ function
- No baseline peripheral or central neuropathy above grade 1
Exclusion
- Hypersensitivity to Cremophor EL
- Pregnant or Lactating
- Spinal Cord Compression
- Pre-existing dementia/cognitive disfunction
- Require Neupogen or Neulasta to Maintain Neutrophil Count
- Have Primary Brain Cancer
- Have History of Ischemic Heart Disease
- Have Diabetes
Key Trial Info
Start Date :
December 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2008
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT00393965
Start Date
December 1 2005
End Date
February 1 2008
Last Update
February 13 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
MD Anderson Cancer Center
Houston, Texas, United States, 77030